CSNK1A1 and myelodysplastic syndrome: A well-known example, leukemic del(5q) myelodysplastic syndrome cells, are haplo-insufficient for CK1α and these cells are sensitized to lenalidomide therapy that specifically targets CK1α for degradation [36].